黑料网

Neonatal hypoglycaemia; Blood glucose; Newborns; Management; Etiology; Screening

Introduction

Neonatal hypoglycemia is a condition characterized by low blood glucose levels in newborns, posing a significant risk for immediate and long-term neurological damage. Blood glucose levels are critical for brain metabolism, and infants are particularly vulnerable due to their limited glycogen stores and immature metabolic pathways. Understanding the risk factors [1], effective diagnostic strategies, and management approaches is essential for healthcare providers to ensure the health and well-being of affected infants.

Etiology of neonatal hypoglycemia

The causes of neonatal hypoglycemia can be broadly categorized into three groups: infant-related factors, maternal factors, and perinatal conditions.

Infant-related factors

Certain characteristics and conditions in the newborn can increase the risk of hypoglycemia, including:

Prematurity: Premature infants often have lower glycogen stores and immature insulin regulation, making them more susceptible to hypoglycaemia [2].

Low birth weight: Infants with a birth weight less than 2500 grams are at increased risk.

Intrauterine growth restriction (IUGR): IUGR infants may have compromised metabolic functions, leading to hypoglycemia.

Congenital metabolic disorders: Conditions such as galactosemia, congenital hyperinsulinism, and glycogen storage diseases can affect glucose metabolism.

Maternal factors

Maternal health plays a significant role in neonatal glucose regulation:

Diabetes mellitus: Infants born to mothers with diabetes are at risk of hypoglycemia due to increased insulin production in response to elevated maternal blood glucose levels [3].

Medications: Certain medications taken by mothers during pregnancy, such as β-blockers or antihypertensives, can contribute to neonatal hypoglycemia.

Maternal malnutrition: Insufficient maternal nutrition can affect fetal growth and metabolic readiness, leading to hypoglycemia.

Perinatal conditions

Various perinatal factors can influence the incidence of neonatal hypoglycemia:

Birth trauma: Injuries during delivery may affect the newborn’s ability to regulate blood glucose levels.

Delayed feeding: Delays in the initiation of breastfeeding or formula feeding can lead to low glucose levels in newborns [4].

Hypothermia: Low body temperature can impair glucose production and utilization, increasing the risk of hypoglycemia.

Diagnosis of neonatal hypoglycemia

Timely diagnosis is essential for preventing complications associated with neonatal hypoglycemia. Screening protocols vary, but certain guidelines are commonly followed:

Risk assessment

Infants at high risk for hypoglycemia, such as those with the aforementioned risk factors, should undergo blood glucose monitoring within the first hours of life [5]. The American Academy of Pediatrics recommends screening for all infants at risk, with the initial blood glucose check typically performed within the first hour postnatally.

Clinical symptoms

Clinical signs of hypoglycemia in neonates may include:

Jitteriness or tremors

Poor feeding

Lethargy or decreased activity

Seizures

Hypotonia (decreased muscle tone)

It is important to note that some infants may exhibit no obvious symptoms despite having low blood glucose levels [6].

Blood glucose measurement

A blood glucose level below 40 mg/dL (2.2 mmol/L) is indicative of hypoglycemia. Point-of-care testing with a glucose meter is commonly used, but laboratory confirmation through venous sampling is recommended for accurate diagnosis and management.

Management of neonatal hypoglycemia

The management of neonatal hypoglycemia focuses on correcting low blood glucose levels and addressing the underlying causes.

Immediate treatment

Upon diagnosis, prompt intervention is critical:

Feeding: For infants who are able to feed, breastfeeding or formula feeding is the first line of treatment to raise blood glucose levels. Early feeding can prevent hypoglycemia from recurring [7].

Oral glucose gel: If the infant is not feeding well or is at risk of hypoglycemia, an oral glucose gel may be administered, providing a quick source of glucose.

Intravenous glucose administration

In cases of severe hypoglycemia (often defined as blood glucose levels <30 mg/dL or if symptoms are present), intravenous dextrose may be required [8]. A typical initial treatment may include:

Dextrose 10% solution: Administered intravenously at a bolus dose, followed by a continuous infusion if needed to maintain stable blood glucose levels.

Monitoring

Close monitoring of blood glucose levels is essential after treatment. Regular checks should continue until the infant demonstrates stable blood glucose levels and the underlying causes are addressed [9].

Long-term management

Infants with recurrent hypoglycemia may require further investigation to determine any underlying metabolic disorders. In cases where congenital hyperinsulinism or other metabolic issues are suspected, referral to a pediatric endocrinologist may be warranted.

Long-term implications

The long-term effects of neonatal hypoglycemia can vary depending on the severity and duration of the hypoglycemic episodes [10]. Some studies suggest that severe or prolonged hypoglycemia may lead to neurodevelopmental delays, cognitive impairment, or other neurological issues. However, with prompt recognition and effective management, most infants with mild to moderate hypoglycemia recover without significant long-term effects.

Conclusion

Neonatal hypoglycemia is a common yet potentially serious condition that requires early detection and appropriate management. Understanding the causes, effective diagnostic strategies, and management options is crucial for healthcare providers working with newborns. By implementing proactive screening protocols and providing timely interventions, the risk of adverse outcomes can be significantly reduced. A multidisciplinary approach, involving pediatricians, nurses, dietitians, and family support, is vital to ensure optimal care for infants at risk of neonatal hypoglycemia.

1. Kruk ME, Gage AD (2018) Lancet Glob Health 6: 1196-1252.

, ,

2. Johnson CD, Haldeman S (2018) Eur Spine J 27: 925-945.

, ,

3. Dent M, Paho M (2015) J. Health Organ. Manag 29: 546-555.

, ,

4. Bombard Y, Baker GR, Orlando E (2018) Implement Sci 13: 98.

, ,

5. Ferrante S (2016) Appl Clin Inform 7: 191-210.

, ,

6. Bisognano M, Schummers D (2014) BMJ 349: 5852.

, ,

7. Viitanen J, Valkonen P (2022) Yearb Med Inform 31: 136-145.

, ,

8. Pawloski PA, Brooks GA (2019) J Natl Compr Canc Netw 17: 331-338.

, ,

9. Conrad DA, Dowling WL (1990) Health Care Manage Rev 15: 9-22.

, ,

10. Davies EL, Bulto LN (2023) J Adv Nurs 79: 83-100.

, ,